Eleventh Annual
Cardiovascular Disease Prevention
International Symposium

February 14-17, 2013
Fontainebleau Hotel, Miami Beach, Florida

Symposium Directors
Michael Ozner, M.D., FACC, FAHA
Theodore Feldman, M.D., FACC, FACP
Arthur Agatston, M.D., FACC

For Symposium Details and Registration, go to MiamiCVDPrevention.BaptistHealth.net.
Educational Objectives

Upon completion of this symposium, participants should be better able to:

Thursday, February 14
- Review the vascular biology of atherosclerosis.
- Examine the retention of apoB lipoproteins with proteoglycans as the initiating factor in atherogenesis.
- Discuss the importance of global cardiovascular risk reduction for the treatment and prevention of atherosclerosis.
- Examine the dietary factors associated with improved cardiovascular health.
- Discuss the cardiovascular benefits of adherence to a Mediterranean-type diet and the potentially beneficial impact of moderate alcohol consumption on cardiovascular disease (CVD) prevention.
- Define the concept of caloric balance in weight management.
- Examine the research that can help clarify the roles of emerging biomarkers and lipid fractions other than LDL cholesterol in the prevention, diagnosis and treatment of CVD.
- Review sterol/stanol biochemistry and the biomarkers related to cholesterol absorption and synthesis.
- Correlate markers of absorption/syntheses to atherosclerotic risk.
- Identify the roles of lipids and lipoproteins in cardiovascular risk.
- Explain the impact of cholesteryl ester transfer protein and proprotein convertase subtilisin/kexin type 9 inhibitors in CVD.
- Examine the typical treatment of a heart attack patient before 1950.
- Determine the extent of atherosclerosis in patients with non-fatal and fatal coronary disease.
- Explain the impact of coronary disease on patients with peripheral vascular disease symptoms.
- Implement more efficacious LDL-lowering decisions when utilizing biomarkers of cholesterol synthesis and absorption.
- Formulate a plan to motivate patients to embrace regular physical exercise as the "magical ingredient" — an effective means of CVD prevention.
- Explain the relationship between exercise and CVD risk reduction and some of the mechanisms of the cardiovascular benefits of exercise.

Friday, February 15
- Review recent clinical evidence demonstrating the connection between obesity and co-morbid conditions.
- Analyze the impact of weight loss on reducing risk factors related to blood pressure, diabetes, CVD and renal disease.
- Examine the newest medical and surgical options for weight loss and identify appropriate candidates for these treatment approaches.
- Explain how inadequacies in the body's defense mechanisms can lead to smoldering chronic inflammation.
- Implement evidence-based best-practice strategies that support early diagnosis and treatment of insulin resistance and CVD reduction.
- Utilize both traditional and novel biomarkers to evaluate and manage cardiovascular risk.
- Analyze the data and outcomes of CRP, apoB and LDL-P as a predictor of cardiovascular risk and evaluate the cost effectiveness of this diagnostic approach.
- Review and discuss the updated guidelines for blood cholesterol, high blood pressure and obesity as well as an integrated cardiovascular risk reduction guideline.
- Compare the basic relationship of the sympathetic nervous system to the cardiovascular system, and describe the fundamental issues in accomplishing preservation from a technical point of view.
- Examine the data available for sympathetic denervation, and describe the role it will fill in managing patients with severe and resistant hypertension, diabetes and other maladies.
- Follow evidence-based recommendations for use of global risk assessment, biomarkers and other tests for assessing CVD risk in asymptomatic patients.
- Evaluate the pros and cons of using different risk assessment and screening strategies in the asymptomatic patient.
- Examine the roles of LDL-C, non-HDL-C and measures of LDL particle number (apoB and LDL-P) for CHD risk prediction.
- Recognize the impact of chromosome 4q25 variants and the risk for atrial fibrillation and ablation failure.
- Discuss recommended changes for the new Adult Treatment Panel (ATP) IV Guidelines, and examine the expected impact on implementation and outcomes in clinical practice.
- Explain the basic aspects of gene analysis.
- Describe the role genetic polymorphisms play in explaining part of residual risk.
- Examine chromosome 9p21.3 as a risk predictor of coronary artery disease and disease progression.
- Describe how undiagnosed obstructive sleep apnea, with or without symptoms, is independently associated with the increased likelihood of arrhythmias, hypertension, CVD and stroke.
- Distinguish which therapies are not useful/effective, and which therapies may be harmful for CVD prevention in women.
- Discuss newly published results of the Kronos Early Estrogen Prevention Study (KEEPS) on the effects of selective initiation of Menopausal Hormone Therapy (MHT) on protection against atherosclerosis.
- Explain the mechanisms for the discrepancies in effects of MHT on risk of CVD based on observational studies and recent randomized clinical trials.
- Determine the degree of atherosclerosis benefit or risk of early-start MHT.
- Examine the epidemiology and assess the cardiovascular risk for people with metabolic syndrome and diabetes.
- Discuss the findings and implications of the latest clinical trials involving glycemic, blood pressure and lipid control in people with diabetes.
- Review and consider implementation of the most recent lifestyle and pharmacologic treatment recommendations to reduce CVD risk in people with metabolic syndrome and diabetes.
- Implement an effective diagnostic workup to screen adult and pediatric patients for familial hypercholesterolemia.
- Formulate new approaches to managing familial hypercholesterolemia.

Saturday, February 16
- Examine coronary artery calcium (CAC) imaging as a patient selection tool for initiating statin therapy.
- Explore the addition of imaging to traditional risk factor assessment to identify people at greatest risk for subsequent CVD events.
- Delineate the merits of blood tests versus imaging in guiding treatment of low-risk patients.
- Utilize carotid ultrasound results to refine the risk prediction in the intermediate-risk patient in order to better determine the need for statin and aspirin therapy.
- Assess the prognostic significance of the rate of change in carotid intima-media thickness (IMT) in CVD event prediction.
- Compare the prognostic significance of baseline measurements of carotid IMT and plaque versus those of coronary calcification in the primary prevention setting.
- Examine the potential use of coronary CTA in CVD prevention.
- Identify the strengths and limitations of using coronary CTA versus coronary artery calcium score for screening/prevention.
- Recognize the prognostic value of coronary plaque identified by coronary CTA.
- Explore the mechanisms of mental stress ischemia, and define the risk factors for acute coronary events.
- Utilize the imaging modalities that will best facilitate the assessment of plaque inflammation in vulnerable patients.
- Integrate vascular imaging and advanced blood testing to assess and predict the risk for coronary heart disease prior to the onset of symptoms.
- Explain the new comprehensive primary and secondary prevention guidelines.
- Recognize and advance the efforts of the Centers for Disease Control and Prevention-sponsored Million Hearts Initiative to significantly reduce the numbers of new and recurrent heart attacks and strokes.
- Implement a framework for clinicians and patients to engage in the comprehensive lifestyle and pharmacologic strategies for CVD prevention.
- Discuss recommended changes for the new Adult Treatment Panel (ATP) IV Guidelines, and examine the expected impact on implementation and outcomes in clinical practice.
- Explain the basic aspects of gene analysis.
- Describe the role genetic polymorphisms play in explaining part of residual risk.
- Examine chromosome 9p21.3 as a risk predictor of coronary artery disease and disease progression.
- Describe how undiagnosed obstructive sleep apnea, with or without symptoms, is independently associated with the increased likelihood of arrhythmias, hypertension, CVD and stroke.
 implementation strategies to decrease the high prevalence and associated morbidity of obstructive sleep apnea.
- Recognize how cholesterol affects cardiovascular risk and identify when, how and whom to treat.
- Describe how the 55-year history of lipoprotein subclass science started at the Lawrence Berkeley National Laboratory (University of California).
- Explain the interaction of triglycerides and HDL-C in the prediction of small LDL pattern B.
- Review the results of the NIH clinical trials that address the impact of lipoprotein heterogeneity on coronary artery disease prediction and response to treatment.
- Describe the impact of lifestyle and medications on lipoprotein heterogeneity.

Sunday, February 17
- Explain the epidemiology of psychosocial risk factors that promote atherosclerosis and coronary heart disease.
- Examine the basic pathophysiological mechanisms induced by psychosocial stress.
- Implement practical approaches toward managing psychosocial stress in cardiovascular practice.

Faculty

Michael Ozner, M.D., FAHA
Symposium Director
Medical Director, Center for Prevention and Wellness, Baptist Health South Florida
Voluntary Assistant Professor of Medicine (Cardiology), University of Miami Miller School of Medicine
Miami, Florida

Theodore Feldman, M.D., FACC, FACP
Symposium Director
Medical Director, South Miami Heart Center
Medical Director, Center for Prevention and Wellness, Baptist Health South Florida
Clinical Associate Professor of Medicine, Florida International University Herbert Wertheim College of Medicine
Miami, Florida

Arthur Agatston, M.D., FACC
Symposium Director
Medical Director, Center for Prevention and Wellness, Baptist Health South Florida
Cardiologist, Baptist Hospital of Miami
Associate Professor of Medicine, University of Miami Miller School of Medicine
Miami, Florida

Ron Blankstein, M.D., FACC
Associate Physician, Cardiovascular Imaging and Preventive Cardiology
Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital
Assistant Professor of Medicine and Radiology, Harvard Medical School
Boston, Massachusetts

Roger Blumenthal, M.D.
Professor of Medicine
Director of Johns Hopkins Ciccarone Preventive Cardiology Center, Johns Hopkins Hospital
Baltimore, Maryland

Eliot Brinton, M.D.
Scientific Advisor, Kronos Longevity Research Institute
Director of the Metabolism Section of Cardiovascular Genetics and Associate Professor, University of Utah School of Medicine
Salt Lake City, Utah

William Cromwell, M.D., FAHA, FNLA
Diplomate, American Board of Clinical Lipidology
Chief, Division of Atherosclerosis and Lipoprotein Disorders
Presbyterian Cardiovascular Institute
Medical Director, Novant Heart and Wellness Raleigh, North Carolina

William Cushman, M.D.
Professor of Preventive Medicine
University of Tennessee College of Medicine
Chief, Preventive Medicine Section
Veterans Affairs Medical Center
Memphis, Tennessee

Tara Dall, M.D.
Medical Director, Advanced Lipidology Early Detection Center for Heart Disease and Diabetes
Delafield, Wisconsin

Michael Davidson, M.D., FACC, FACP, FNLA
Clinical Professor, Director of Preventive Cardiology, University of Chicago Pritzker School of Medicine
Chicago, Illinois

Thomas Dayspring, M.D., FACP, FNLA, NCMP
Director of Cardiovascular Education
Foundation for Health Improvement and Technology
Richmond, Virginia

Jonathan Falkow, M.D., FACC, FAHA, FABC
Medical Director of Clinical Cardiology, EKG, Stress Lab and Cardiac Rehabilitation
Baptist Cardiac & Vascular Institute
Co-Medical Director of the Chest Pain Center
Baptist Hospital of Miami
Miami, Florida

William Harris, Ph.D.
Research Professor in the Department of Medicine, Sanford School of Medicine
University of South Dakota
Adjunct Senior Scientist at the Cardiovascular Health Research Center, Sanford Research
Sioux Falls, South Dakota

Barry Katzen, M.D., FACC, FCR, FSIR
Founder and Medical Director, Baptist Cardiac & Vascular Institute
Associate Dean, Clinical Affairs, Baptist Health Clinical Professor of Radiology and Surgery
Florida International University Herbert Wertheim College of Medicine
Miami, Florida

Spencer King, III, M.D., MACC, FSCAI, FESC
President, Heart and Vascular Institute
St. Joseph's Hospital
Atlanta, Georgia

Harlan Krumholz, M.D.
Harold H. Hines Jr. Professor of Medicine (Cardiology)
Professor of Investigative Medicine and of Public Health (Health Policy)
Director, Clinical Scholars Program
Director, Yale-New Haven Hospital Center for Outcomes Research and Evaluation
New Haven, Connecticut

Joseph McConnell, Ph.D.
Chief Medical Officer and Co-founder
Health Diagnostic Laboratory
Richmond, Virginia

Khurram Nasir, M.D.
Research Director, Center for Prevention and Wellness
Director, High-risk Cardiovascular Disease Clinic
Baptist Health South Florida, Miami, Florida
Assistant Professor, Johns Hopkins Ciccarone Center for Preventive Cardiology
Baltimore, Maryland

Paul Ridker, M.D., MPH, FACC, FAHA
Director, Center for Cardiovascular Disease Prevention, Division of Preventive Medicine
Baptist Health South Florida
Eugene Braunwald Professor of Medicine
Harvard Medical School
Boston, Massachusetts

William Roberts, M.D.
Executive Director, Baylor Heart and Vascular Institute
Baylor University Medical Center
Dallas, Texas

Alan Rozanski, M.D.
Interim Chief, Division of Cardiology
St. Luke's-Roosevelt Hospitals
New York, New York

Robert Soufer, M.D.
Professor of Medicine (Cardiology)
Yale School of Medicine
Chief, Cardiovascular Medicine
Veterans Affairs/Connecticut Healthcare System
New Haven, Connecticut

Laurence Sperling, M.D., FACC, FACP, FAHA
Professor of Medicine (Cardiology)
Director, The Center for Heart Disease Prevention
Emory University School of Medicine
Atlanta, Georgia

Robert Superko, M.D.
Executive Director, Center for Genomics and Human Health, Translational Research Institute at St. Joseph's Hospital
Atlanta, Georgia

Ahmed Tawakol, M.D.
Co-director, Cardiac MR PET CT Program
Massachusetts General Hospital
Boston, Massachusetts

Nanette Wenger, M.D., MACC, MACP, FAHA
Professor of Medicine (Cardiology) Emeritus
Emory University School of Medicine
Consultant, Emory Heart and Vascular Center
Atlanta, Georgia

Nathan Wong, Ph.D., FACC, FAHA
Professor and Director, Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine
Immediate Past President, American Society for Preventive Cardiology
Irvine, California
Statement of Need
A key strategy for addressing heart disease and stroke is to educate the public and healthcare practitioners about the importance of prevention. When healthcare providers perform consistent risk factor assessments, more patients can be properly diagnosed and medically managed to prevent cardiovascular disease. Both primary and secondary prevention, as well as new developments in the diagnosis, treatment and prevention of cardiovascular disease, need to be addressed.

Target Audience
- Cardiologists
- General Internists
- Family Practitioners
- Endocrinologists
- Psychologists
- Physician Assistants
- Nurse Practitioners
- Nurses
- Pharmacists
- Dietitians
- Respiratory Therapists
- Healthcare professionals involved in the diagnosis, treatment and prevention of cardiovascular disease

Cardiovascular disease is the leading cause of death for men and women in the United States and throughout the world. More than ten years ago I established this symposium dedicated to the treatment and prevention of heart attack and stroke. I am pleased that it has become one of the most prestigious and widely attended symposiums on cardiovascular disease prevention worldwide. This is the result of the outstanding world-renowned faculty of experts who share expertise and engage in discussions on a wide range of topics clinically pertinent to the practicing physician and healthcare provider interested in cardiovascular disease prevention. I am confident that this symposium will exceed your expectations and I look forward to seeing you February 14th through the 17th at the beautiful Fontainebleau Hotel in Miami Beach.

Michael Ozner, M.D.

On behalf of Baptist Health, I’d like to invite you to the 11th Annual Cardiovascular Disease Prevention Symposium. Our 2013 meeting has expanded to become a world-class symposium that travels beyond the world of preventive cardiology. As doctors, we’ve become pretty good at fixing the engine when it’s broken, so to speak. But it’s time for the old definition of good health as the absence of disease to be turned on its head. It’s time to focus on wellness and how we can help patients achieve that level of physical, emotional, spiritual and psychological good health that paints the bigger picture of well-being. While we’ll still focus on cardiology and have sessions filled with data and evidence-based best practices on everything from heart disease to diabetes and obesity, we’ll be heading deeper into the realm of wellness and prevention than ever before. I challenge you to find another meeting with three conference directors — myself, Dr. Arthur Agatston and Dr. Michael Ozner — who, with more than 25 years of practice each, are as passionate about prevention and wellness. We look forward to seeing you at this dynamic symposium.

Theodore Feldman, M.D.

Heart disease is preventable, but it can’t be averted simply by following national guidelines. If you want to bust the many myths of treating and preventing heart disease, join us on February 14th through the 17th at the Fontainebleau Miami Beach Hotel. You’ll be able to hear and interact with the experts and learn more about the latest advances in wellness and prevention. In the area of imaging, we’ll discuss the misunderstandings about cardiac imaging, when and how to do preventive screenings, the ins and outs of calcium scoring, and how CT angiography can be used as an important predictor of future coronary events. In addition, the newest information in nutrition and exercise will be presented. The entire package will bring you to a higher level of sophistication and quality of care for your patients. Mark your calendar now for one of the best continuing medical education opportunities available in the area of cardiovascular wellness and prevention. See you in Miami Beach.

Arthur Agatston, M.D.

Baptist Health South Florida

Baptist Health South Florida is the largest not-for-profit healthcare organization in the region. Affiliates of Baptist Health include Baptist Hospital of Miami, Baptist Children’s Hospital, South Miami Hospital, Homestead Hospital, Mariners Hospital, Doctors Hospital, West Kendall Baptist Hospital, Baptist Cardiac & Vascular Institute and Baptist Outpatient Services. For more information about Baptist Health, go to BaptistHealth.net.
Thursday, February 14

7:15 a.m.  Registration, Continental Breakfast and Visit Exhibits
7:50 a.m.  Welcome and Introductions

SESSION I
Moderator: Michael Ozner, M.D.
8:00 a.m.  The 21st Century Paradigm Shift: Comprehensive Cardiovascular Risk Reduction for the Treatment and Prevention of Atherosclerosis
           Michael Ozner, M.D.
8:30 a.m.  The Optimal Diet for Cardiovascular Health
           Lawrence Sperling, M.D.
9:00 a.m.  Inflammation in Atherosclerosis: A Look to the Future
           Paul Ridker, M.D.
9:30 a.m.  Plasma Sterol/Stanol Measurements and Cardiovascular Risk
           Thomas Dayspring, M.D.
10:00 a.m. Break and Visit Exhibits
10:30 a.m. Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most Out of New and Old Biomarkers
           William Cromwell, M.D.
11:00 a.m. The Yin and Yang of New Lipid-modifying Agents: CETP Inhibitors — Are They on Life Support? PCSK9 Inhibitors — Are They Potential Game Changers?
           Thomas Dayspring, M.D.
11:20 a.m. Patient Management Session: Case Studies With Faculty Discussion and Audience Participation
           William Cromwell, M.D., Lawrence Sperling, M.D., Thomas Dayspring, M.D., Paul Ridker, M.D.

SESSION II - Keynote Presentation and Luncheon
12:00 noon  Cardiovascular Disease Prevention: Clinical Pearls After Five Decades of Research
           William Roberts, M.D.

SESSION III
Moderator: Michael Ozner, M.D.
1:30 p.m.  Advanced Risk Stratification in the Intermediate-risk Patient: CRP, LDL-P or CAC?
           Roundtable Discussion: William Cromwell, M.D., Khurram Nasir, M.D., Paul Ridker, M.D.
2:30 p.m.  Treatment Nomogram Based on Cholesterol Synthesis/Absorption Markers
           Thomas Dayspring, M.D.
3:00 p.m.  The Great Debate: Treatment Should Be Based on CVD Risk Rather than LDL Targets
           Protagonist: Harlan Krumholz, M.D.
           Antagonist: Thomas Dayspring, M.D.
4:00 p.m.  The Role of Exercise in Cardiovascular Disease Risk Reduction: Does It Make a Difference?
           Laurence Sperling, M.D.
4:30 p.m.  Patient Management Session: Case Studies With Faculty Discussion and Audience Participation
           William Cromwell, M.D., Laurence Sperling, M.D., Thomas Dayspring, M.D., Paul Ridker, M.D., Harlan Krumholz, M.D.
5:00 p.m.  Adjourn

Friday, February 15

7:15 a.m.  Registration, Continental Breakfast and Visit Exhibits

SESSION IV
Moderator: Theodore Feldman, M.D.
8:00 a.m.  The Obesity Epidemic: The Role of New Pharmaceutical Agents and Surgical Interventions
           Theodore Feldman, M.D.
8:30 a.m.  “Smoldering” Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease
           Eliot Brinton, M.D.
9:00 a.m.  Advanced Lipid Testing: Case-based Applications
           Tara Dall, M.D.
9:30 a.m.  Hypertension Update
           William Cushman, M.D.
10:00 a.m. Break and Visit Exhibits
10:30 a.m. Catheter-based Renal Sympathetic Denervation for Resistant Hypertension
           Barry Katzen, M.D.
10:45 a.m. Evidence-based Guidelines for Cardiovascular Risk Assessment in Asymptomatic Patients
           Nathan Wong, Ph.D.
11:15 a.m. Patient Management Session: Case Studies With Faculty Discussion and Audience Participation
           Eliot Brinton, M.D., William Cushman, M.D., Tara Dall, M.D., Barry Katzen, M.D., Nathan Wong, Ph.D.
12:00 noon  Lunch

SESSION V
Moderator: Theodore Feldman, M.D.
1:00 p.m.  LDL-C, Non-HDL-C, Measures of LDL Particle Number (apoB and LDL-P): And the Winner Is...
           William Cromwell, M.D.
1:30 p.m.  Show Your Heart You Care: Effectiveness-based Guidelines for the Prevention of Cardiovascular Disease in Women
           Nanette Wenger, M.D.
2:00 p.m.  Is There a Role for Hormone Replacement Therapy for CVD Prevention in Select Postmenopausal Women?
           Eliot Brinton, M.D.
2:30 p.m.  The Use of Estrogen in Postmenopausal Women: Controversy and Consensus
           Roundtable Discussion: Nanette Wenger, M.D., Eliot Brinton, M.D., Tara Dall, M.D.
3:00 p.m.  Break and Visit Exhibits
3:30 p.m.  Metabolic Syndrome and Diabetes: Evaluating CVD Risk and Strategies for CVD Risk Reduction
           Nathan Wong, Ph.D.
4:00 p.m.  Familial Hyperlipidemia: Clinical Pearls for Diagnosis and Management
           Tara Dall, M.D.
4:30 p.m.  Patient Management Session: Case Studies With Faculty Discussion and Audience Participation
           Eliot Brinton, M.D., Tara Dall, M.D., Nanette Wenger, M.D., William Cromwell, M.D., Nathan Wong, Ph.D.
5:00 p.m.  Adjourn

Every effort will be made to adhere to the schedule; however, changes may occur. For the most up-to-date schedule, please visit us at MiamiCVDPrevention.BaptistHealth.net.

Photography and recording of any kind are strictly prohibited in the symposium and event areas.
Saturday, February 16
7:15 a.m.  Registration, Continental Breakfast and Visit Exhibits

SESSION VI
Moderator: Arthur Agatston, M.D.
8:00 a.m.  Lessons From MESA: Are We Ready for a Paradigm Shift From Risk Factors to Detection of Subclinical Coronary Atherosclerosis?
Khurram Nasir, M.D.
8:30 a.m.  Carotid Plaque Imaging: Where Do We Stand?
Roger Blumenthal, M.D.
9:00 a.m.  The Evolving Role of Coronary CTA in Primary Cardiovascular Disease Prevention: Are We There Yet?
Ron Blankstein, M.D.
9:30 a.m.  From Neurons to Myocytes: Imaging the Emotional Brain and Stressful Heart
Robert Soufer, M.D.
10:00 a.m.  Break and Visit Exhibits
10:30 a.m.  Imaging Plaque Inflammation in Vulnerable Patients: What Do We Know and What Are We Looking For?
Ahmed Tawakol, M.D.
11:00 a.m.  Integrating Vascular Imaging and Advanced Blood Testing for the Prevention of Coronary Heart Disease
Arthur Agatston, M.D.
11:30 a.m.  Patient Management Session: Case Studies With Faculty Discussion and Audience Participation
Arthur Agatston, M.D., Ron Blankstein, M.D., Roger Blumenthal, M.D., Khurram Nasir, M.D., Robert Soufer, M.D., Ahmed Tawakol, M.D.
12:00 noon  Lunch

SESSION VII
Moderator: Michael Ozner, M.D.
1:00 p.m.  ABCDE of Primary Cardiovascular Disease Prevention: Can We Make a Difference?
Roger Blumenthal, M.D.
1:30 p.m.  ATP IV: How the New Guidelines Will Affect Your Practice
Michael Davidson, M.D.
2:00 p.m.  Practical Genetics for Heart Disease Prevention
Robert Superko, M.D.
2:30 p.m.  Break and Visit Exhibits
3:00 p.m.  Sleep Apnea: The Often Neglected Cardiovascular Disease Risk Factor
Jonathan Fialkow, M.D.
3:30 p.m.  HDL-cholesterol: Whom Should We Treat? When Should We Treat? How Should We Treat?
Michael Davidson, M.D.
4:00 p.m.  LDL and HDL Subclasses: Use and Misuse in the Community
Robert Superko, M.D.
4:30 p.m.  Question-and-Answer Session With Audience Participation
Roger Blumenthal, M.D., Michael Davidson, M.D., Robert Superko, M.D., Jonathan Fialkow, M.D.
5:00 p.m.  Adjourn

Sunday, February 17
7:15 a.m.  Registration, Continental Breakfast and Visit Exhibits

SESSION VIII
Moderator: Michael Ozner, M.D.
8:00 a.m.  Integrating Psychological Approaches Into the Behavioral Management of Modifiable Risk Factors in Primary Prevention
Alan Rozanski, M.D.
8:30 a.m.  Lipoprotein a (Lp(a)): Should We Measure? Should We Treat?
Joseph McConnell, Ph.D.
9:00 a.m.  Omega-3, Omega-6 and Omega-9: Are They All Important for Cardiovascular Health?
William Harris, M.D.
9:30 a.m.  Is There a Role for Coronary Intervention in Stable Coronary Artery Disease?
Spencer King, M.D.
10:00 a.m.  Break and Visit Exhibits
10:30 a.m.  Can We Optimize Individual Care Without Knowledge of Particle Number?
William Cromwell, M.D.
11:00 a.m.  Omega-3 Update: What Do the New Agents Bring to the Table?
William Harris, M.D.
11:30 a.m.  Is HDL-P a Better Predictor of CVD Risk than HDL-C?
Joseph McConnell, M.D.
12:00 noon  Question-and-Answer Session With Audience Participation
Alan Rozanski, M.D., Joseph McConnell, Ph.D., William Harris, M.D., Spencer King, M.D.
12:30 p.m.  Adjourn

Accreditation and Credits
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Baptist Health South Florida designates this live activity for a maximum of 26 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Application for credit has been filed with the American Academy of Family Physicians.

Disclosure and Resolution of Conflict of Interest
Baptist Health South Florida requires resolution of all conflicts of interest to ensure balance, independence, objectivity and scientific rigor in all CME programming. Conflicts of interest of all individuals who control CME content will be identified and resolved prior to this symposium. Full disclosure will be made in the symposium reference guide. Presenters will also disclose discussion of off-label uses.

This does not apply to M.D.s and D.O.s

Terms Regarding Partial Credit — Partial credit is not available. Where credits are approved on a session-by-session basis, participants must attend each session in its entirety to receive complete credit for the session. This does not apply to M.D.s and D.O.s, who are responsible for claiming credit commensurate with the amount of time they participate in the session/symposium.

Baptist Health South Florida has been designated as a Category 1继续教育活动，为医学教育提供继续医疗教育。Baptist Health South Florida认可该活动为26个AMA PRA一类学分。医生应仅申报与其参与活动程度相称的学分。

申请学分已提交给美国家庭医学院。
**Location and Accommodations**

Fontainebleau Hotel ■ 4441 Collins Avenue, Miami Beach, Florida 33140

Telephone: 800-548-8886 ■ Website and Reservations: fontainebleau.com

The famous Fontainebleau Miami Beach Hotel is a spectacular blend of Golden Era glamour and modern luxury. At Fontainebleau, striking design, contemporary art, music, fashion and technology merge into a vibrant new kind of guest experience, making this the most dynamic destination resort on the eastern seaboard. Following a $1 billion renovation of this 1954 landmark, the 22-acre oceanfront hotel features signature restaurants by award-winning chefs; two chic nightlife venues; a two-story, 40,000-square-foot spa; an expansive poolscape and a pristine Atlantic Ocean beach. The Fontainebleau Hotel is 20 minutes from Miami International Airport and 35 minutes from Ft. Lauderdale/Hollywood International Airport.

Make your hotel reservation now by calling 800-548-8886 or go to fontainebleau.com to receive the special group rate of $329, plus applicable taxes. Group rates will be honored through Friday, January 11, 2013, based on availability.

**Location ■ Attractions ■ Events**

Miami Beach is Florida’s picture-postcard winter playground. South Beach — often called the American Riviera and an Art Deco Playground — offers an eclectic mix of world-class boutiques, galleries, museums and stores. It is also a culinary hot spot for gourmet, ethnic and casual cuisine. Nearby destination neighborhoods, including Coconut Grove, Miami Design District, Coral Gables and Bayside, which is adjacent to the Port of Miami, offer endless options for shopping, dining and people watching. From Vizcaya Museum and Gardens to Everglades National Park, activities and attractions are available to suit every interest. See our symposium website for links to special events taking place before, during and after the symposium dates, including the Miami International Boat Show and Strictly Sail (February 14-18), Coconut Grove Arts Festival (February 16-18) and the South Beach Wine and Food Festival (February 21-24).

**Symposium Registration**

The registration fee includes tuition, daily continental breakfast, break refreshments and lunch. To expedite registration, go to MiamiCVDPrevention.BaptistHealth.net. Confirmations will be sent for registrations received by Monday, January 14. Registrations cannot be processed or confirmed without full payment.
Symposium Registration

Thursday-Sunday, February 14-17, 2013
Fontainebleau Miami Beach Hotel
Register online at MiamiCVDPrevention.BaptistHealth.net.

Please register by January 14, 2013.

Name (Please print clearly)

Degree (Check all that apply):

- [ ] M.D.
- [ ] D.O.
- [ ] Ph.D.
- [ ] PA.
- [ ] ARNP
- [ ] R.N.
- [ ] Pharm.D.
- [ ] Dietitian
- [ ] Respiratory
- [ ] Other _________

Institution Affiliation

Mailing Address

City/State/Zip

Daytime Telephone

Fax

Email Address

License Number

Symposium Rates: Please check all that apply.

- [ ] Physicians* & Psychologists** – $425
- [ ] Other Healthcare Professionals** – $185
- [ ] Physicians in Training*** – $185
- [ ] Baptist Health Employees** – $130

* Group discount available for doctors when three or more register together as a group by January 14. Add-ons will not be accepted. Call for details. (786-596-2398)
** _____ (Initial) I have read and understand the Terms Regarding Partial Credit in the Accreditation and Credits section.
***Registration must be accompanied by a letter from the Fellowship/Residency Director.

Method of Payment:

Credit Card: MiamiCVDPrevention.BaptistHealth.net
Check: Mail registration with check payable to Baptist Health CME Department, to 8900 North Kendall Drive, Miami, Florida 33176-2197

- [ ] We regret that registrations cannot be accepted by telephone or fax.
- [ ] Registrations will be processed after full payment is received.
- [ ] Confirmations will be sent via email for registrations received by January 14.

How did you hear about this symposium? Please check all that apply.

- [ ] Mail
- [ ] Email
- [ ] Internet
- [ ] Previous Attendee
- [ ] Newsletter
- [ ] Other _______________________

Cancellations must be sent in writing and received or postmarked by January 14 to receive a refund of the registration fee, less a $25 administrative fee. Registration fees are not refundable after January 14.

Contact Us: Baptist Health CME Department, 786-596-2398, 8900 North Kendall Drive, Miami, Florida 33176 or CME@BaptistHealth.net.

In consideration of the Americans with Disabilities Act, please check here if you require special services, and we will contact you to determine your specific requirements. Please submit this form by January 14, 2013.